Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Kostos, Louise Kathleen
Lai, William Yu Ching
Lambroglou, Peter
Medhurst, Elizabeth
Buteau, James Patrick
Sandhu, Shahneen
Tran, Ben
Spain, Lavinia Anne
Conduit, Ciara
Wallace, Roslyn
Alipour, Ramin
Akhurst, Timothy J.
Kong, Grace
Cardin, Anthony
Saghebi, Javad
Kumar, Aravind Ravi
Hofman, Michael S.
Azad, Arun
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Mol Imaging & Therapeut Nucl Med, Canc Imaging, Prostate Canc Theranost & Imaging Ctr Excellence, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical protocols to monitor efficacy of [177Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.
    Unterrainer, Lena
    De Leiris, Nicolas
    Unterrainer, Marcus
    Ilhan, Harun
    Delker, Astrid
    Hempel, Linus
    Ells, Zachary
    Zahner, Joseph
    Holzgreve, Adrien
    Zacherl, Mathias J.
    Casuscelli, Jozefina
    Kiraz, Kevin
    Leenhardt, Julien
    Jacquet, Emmanuelle
    Long, Jerome
    Laramas, Mathieu
    Paller, Channing Judith
    Solnes, Lilja B.
    Gafita, Andrei
    Djaileb, Loic
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 39 - 39
  • [2] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Philipp E. Hartrampf
    Franz-Xaver Weinzierl
    Andreas K. Buck
    Steven P. Rowe
    Takahiro Higuchi
    Anna Katharina Seitz
    Hubert Kübler
    Andreas Schirbel
    Markus Essler
    Ralph A. Bundschuh
    Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276
  • [3] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Hartrampf, Philipp E.
    Weinzierl, Franz-Xaver
    Buck, Andreas K.
    Rowe, Steven P.
    Higuchi, Takahiro
    Seitz, Anna Katharina
    Kuebler, Hubert
    Schirbel, Andreas
    Essler, Markus
    Bundschuh, Ralph A.
    Werner, Rudolf A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (09) : 3269 - 3276
  • [4] Therapy-related Myeloid Neoplasms Following Lutetium-177 [177Lu]Lu-PSMA Therapy in patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
    Eifer, M.
    Sutherland, D. E. K.
    Goncalves, I.
    Buteau, J. P.
    Akhurst, T.
    Alipour, R.
    Au, L.
    Azad, A. A.
    Cardin, A.
    Chen, D.
    Emmerson, B.
    Emmett, L.
    Jewell, K.
    Kong, G.
    Kashyap, R.
    Kostos, L.
    Kumar, A. S. Ravi
    Kwan, E. M.
    Macfarlane, L.
    Medhurst, E.
    Saghebi, J.
    Sandhu, S.
    Tran, B.
    Wyatt, A. W.
    Hofman, M. S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S677 - S677
  • [5] Response to [177Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
    Zisser, Lucia
    Yu, Josef
    Oszwald, Andre
    Wollenweber, Tim
    Kretschmer-Chott, Elisabeth
    Grubmueller, Bernhard
    Kramer, Gero
    Shariat, Shahrokh F.
    Mitterhauser, Markus
    Vraka, Chrysoula
    Hacker, Marcus
    Haug, Alexander R.
    Rasul, Sazan
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (11) : 1113 - 1120
  • [6] Factors predicting the early biochemical response to [177Lu]Lu-PSMA therapy in patients with metastatic castration resistant prostate cancer
    Al-Timimi, Ahmed
    Manafi-Farid, Reyhaneh
    Fallahi, Babak
    Beiki, Davood
    Askari, Emran
    Rezaei, Alireza
    Adinehpour, Zohreh
    Eftekhari, Mohammad
    IRANIAN JOURNAL OF NUCLEAR MEDICINE, 2022, 30 (02): : 115 - 121
  • [7] Treatment of castration-resistant metastatic prostate cancer with [177Lu]PSMA radioligand
    Sundset, Rune
    Haugnes, Hege Sagstuen
    Perez, Alexander
    Engelsen, Ola
    Fosseide, Ida H. H.
    Castillejo, Miguel J.
    Bogsrud, Trond Velde
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2024, 144 (09)
  • [8] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Derlin, Thorsten
    Schmuck, Sebastian
    LANCET ONCOLOGY, 2018, 19 (08): : E372 - E372
  • [9] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [10] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    BIOMEDICINES, 2021, 9 (04)
12345